Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Blood Protein Disorders, Cardiovascular Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT Number: NCT06330896
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are:
* genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing * genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients. * disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS. * correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients.
The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 18 months in 498 patients
number and percentage of genetic landscape of FISH and NGS in patients with Plasma Cell Disorders
Time frame: 18 months in MM patients
genetic landscape correlation between FISH and NGS in MM patients
Time frame: 18 months in MM patients
number of genetic landscape in relapse MM patients
Time frame: 18 months
time of survival in MM patients
Time frame: 18 months
time of disease progression in MM patients
Time frame: 18 months in MM patients
number of MM patients who have the different factors such as gender, age, and comorbidities.
Time frame: 18 months in 498 patients
number and percentage of male and female
Time frame: 18 months in 498 patients
age in years
Contact information is provided by the study sponsor or research team.
Chutima Kunacheewa
CONTACT
Weerapat Owattanapanich
CONTACT
Siriraj Hospital
Other
Acronym: genetics MM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04879043
Blood Protein Disorders, Cardiovascular Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial DetailsNCT06870760
Blood Protein Disorders, Cardiovascular Diseases
Charlotte, North Carolina, United States
View Trial DetailsNCT06313502
Neoplasms, Neoplasms by Histologic Type
Little Rock, Arkansas, United States
View Trial Details